^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    JARID2 overexpression

    i
    Other names: JARID2, Jumonji And AT-Rich Interaction Domain Containing 2, Jumonji, AT Rich Interactive Domain 2, Jumonji/ARID Domain-Containing Protein 2, Protein Jumonji, JMJ, Jumonji (Mouse) Homolog, Jumonji-Like Protein, Jumonji Homolog
    Entrez ID:
    3720
    3ms
    Valproic acid regulates the miR-155/Jarid2 axis by affecting miR-155 promoter methylation in glioma. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    VPA downregulates the expression level of miR-155 by increasing the methylation level of the miR-155 promoter, suggesting that the miR-155/JARID2 axis is implicated in VPA inhibition of glioma cell viability and enhancement of glioma cell apoptosis. This study demonstrates a new mechanism of VPA treatment of gliomas by affecting the miR-155/JARID2 axis, which could be regarded as a new strategy for the prevention and treatment of glioma.
    Journal
    |
    MIR155 (MicroRNA 155) • JARID2 (Jumonji And AT-Rich Interaction Domain Containing 2)
    |
    miR-155 overexpression • JARID2 overexpression
    1year
    JARID2 regulates epithelial mesenchymal transition through the PTEN/AKT signalling pathways in ovarian endometriosis. (PubMed, Reprod Biol)
    Accordingly, the opposite results were obtainedwhen JARID2 was downregulated. Furthermore, JARID2 promoted the invasion and migration ability of Ishikawa cells.
    Retrospective data • Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • JARID2 (Jumonji And AT-Rich Interaction Domain Containing 2)
    |
    CDH1 expression • VIM expression • JARID2 overexpression
    over2years
    JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1. (PubMed, Int J Biochem Cell Biol)
    In clinical settings, high expression of JARID2 is significantly associated with advanced TNM stage, shorter overall survival, and poor chemotherapeutic response. These findings point toward an important role of JARID2 in CDDP resistance and stemness of NSCLC and provide a promising target for overcoming CDDP resistance.
    Journal
    |
    NOTCH1 (Notch 1) • SOX2 • JARID2 (Jumonji And AT-Rich Interaction Domain Containing 2)
    |
    JARID2 overexpression
    |
    cisplatin